Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
METABOLIC DISORDERS / RESEARCH LETTER
Atherogenic lipid ratios and insulin resistance primarily reflect adiposity rather than androgen status in adolescents with polycystic ovary syndrome: evidence from a large case-control cohort
1
Department of Pediatrics and Pediatric Endocrinology, School of Medicine, Medical University of Silesia, Katowice, Poland
2
The Doctoral School of the Medical University of Silesia, Katowice, Poland
3
Department of Gynecology, Obstetrics and Gynecological Oncology, Faculty of Health Science, Medical University of Silesia, Katowice, Poland
These authors had equal contribution to this work
Submission date: 2026-02-27
Final revision date: 2026-04-09
Acceptance date: 2026-04-27
Online publication date: 2026-04-30
Corresponding author
Karolina M. Jakubowska-Kowal
Department of Pediatrics and Pediatric Endocrinology School of Medicine Medical University of Silesia Katowice, Poland
Department of Pediatrics and Pediatric Endocrinology School of Medicine Medical University of Silesia Katowice, Poland
Arch Med Sci 2026;22(2):1206-1211
TOPICS
REFERENCES (17)
1.
Peña AS, Witchel SF, Hoeger KM, et al. Adolescent polycystic ovary syndrome according to the international evidence-based guideline. BMC Med 2020; 18: 72.
2.
VanHise K, Wang ET, Norris K, Azziz R, Pisarska MD, Chan JL. Racial and ethnic disparities in polycystic ovary syndrome. Fertil Steril 2023; 119: 348-54.
3.
Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011; 95: 1073-9.e11.
4.
Siegel PM, Katzmann JL, Weinmann-Menke J, et al. A practical guide to the management of dyslipidaemia. Clin Res Cardiol 2026; 115: 185-97.
5.
Mach F, Koskinas KC, Roeters Van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 2025; 409: 120479.
6.
Dobiás˘ová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate inapob-lipoprotein-depleted plasma (FERHDL). Clin Biochem 2001; 34: 583-8.
7.
McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol 2005; 96: 399-404.
8.
Alfahl S, Mohammedsaeed W, Alamri A, et al. Lipid ratios as early screening markers of dyslipidemia in normal-BMI university students: a cross-sectional epidemiologic study. Arch Med Sci Atheroscler Dis 2026; 11: e5-11.
9.
Ulloque-Badaracco JR, Alarcon-Braga EA, Hernandez-Bustamante EA, et al. Triglyceride–glucose index and lipid ratios in women with and without polycystic ovary syndrome: a systematic review and meta-analysis. Ther Adv Endocrinol Metab 2025; 16: 20420188251328840.
10.
Ibáñez L, Oberfield SE, Witchel S, et al. An International Consortium Update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr 2017; 88: 371-95.
11.
Palczewska I, Niedźwiecka Z. Wskaźniki rozwoju somatycznego dzieci i młodzieży warszawskiej. Med Wieku Rozw 2001; 5: 2.
12.
Cabanillas-Lazo M, Quispe-Vicuña C, Pascual-Guevara M, et al. Diagnostic accuracy of triglyceride to glucose index and triglyceride/high-density lipoprotein index for insulin resistance among children and adolescents: a systematic review. Wu Q, editor. PLOS One 2025; 20: e0326179.
13.
Iwani NAKZ, Jalaludin MY, Zin RMWM, et al. Triglyceride to HDL-C ratio is associated with insulin resistance in overweight and obese children. Sci Rep 2017; 7: 40055.
14.
Cussen L, McDonnell T, Miller C, McIlroy M, O’Reilly MW. Polycystic ovary syndrome: origins and implications: polycystic ovary syndrome: the impact of androgen excess on metabolic health. Reproduction 2025; 170: e250102.
15.
Zhao T, Xinghua T, Xiao X, et al. The impact of androgen levels on serum metabolic profiles in patients with polycystic ovary syndrome. Gynecol Endocrinol 2024; 40: 2352136.
16.
O’Reilly MW, Taylor AE, Crabtree NJ, et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab 2014; 99: 1027-36.
17.
Kim CH, Lee SH. Effectiveness of lifestyle modification in polycystic ovary syndrome patients with obesity: a systematic review and meta-analysis. Life (Basel) 2022; 12: 308.
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
